Showing results (21-30 of 65) with videos related to
Sort By:
Pageof 7
Neurology and Therapy|March 10, 2022
Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) InstrumentsCrystal Watson, Kayla Scippa, Arie Barlev, et al.The Journal of Dermatological Treatment|June 7, 2012
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationBenjamin Chastek, Kathleen M Fox, Crystal Watson, et al.Journal of Medical Economics|January 24, 2022
Mean lifetime survival estimates following solid organ transplantation in the US and UKChristopher N Graham, Crystal Watson, Arie Barlev, et al.Journal of Medical Economics|May 13, 2010
Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritisSarah Thayer, Crystal Watson, Rui Song, et al.Advances in Therapy|August 14, 2012
Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settingsMachaon Bonafede, Kathleen M Fox, Crystal Watson, et al.Current Medical Research and Opinion|December 3, 2013
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathyAnna Walker, Crystal Watson, Stamatia T Alexopoulos, et al.The Journal of Dermatological Treatment|February 28, 2013
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingMachaon Bonafede, Barbara H Johnson, Kathleen M Fox, et al.Neurology and Therapy|September 8, 2023
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, et al.Health Security|October 24, 2024
Pandemic Exercises: Lessons for a New Era in Pandemic PreparednessTara Kirk Sell, Crystal R Watson, Lucia Mullen, et al.Advances in Therapy|March 14, 2012
Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisMachaon M K Bonafede, Shravanthi R Gandra, Crystal Watson, et al.Pageof 7